Combination of estramustine, paclitaxel, and tegafur-uracil (ETU) in patients with metastatic hormone-refractory prostate cancer (mHRPC): Efficacy and safety results of a multicenter phase II study

被引：0
|
作者：
Fitoussi, O.
Guichard, F.
Hirt, S.
Dohollou, N.
Bureau, C.
Auduhy, F.
Guichard, P.
机构：
[1] Polyclin Bordeaux N Aquitaine, Bordeaux, France
[2] Merck Lipha Sante, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.16027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16027
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
    Smith, DC
    Chay, CH
    Dunn, RL
    Fardig, J
    Esper, P
    Olson, K
    Pienta, KJ
    CANCER, 2003, 98 (02) : 269 - 276
  • [22] Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer
    Kikuno, Nobuyuki
    Urakami, Shinji
    Nakamura, Shigeru
    Hiraoka, Takeo
    Hyuga, Taijyu
    Arichi, Naoko
    Wake, Kouji
    Sumura, Masahiro
    Yoneda, Tatsuaki
    Kishi, Hirofumi
    Shigeno, Kazushi
    Shiina, Hiroaki
    Igawa, Mikio
    EUROPEAN UROLOGY, 2007, 51 (05) : 1252 - 1258
  • [23] Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer
    Tunckiran, Ahmet
    Bozlu, Murat
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2007, 6 (02): : 36 - 38
  • [24] Phase II study of topotecan in metastatic hormone-refractory prostate cancer
    Hudes, GR
    Kosierowski, R
    Greenberg, R
    Ramsey, HE
    Fox, SC
    Ozols, RF
    McAleer, CA
    Giantonio, BJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) : 235 - 240
  • [25] Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer
    Segawa T.
    Kamoto T.
    Kinoshita H.
    Kunishima Y.
    Yoshimura K.
    Ito A.
    Takahashi T.
    Higashi S.
    Nakamura E.
    Nishiyama H.
    Ito N.
    Yamamoto S.
    Habuchi T.
    Ogawa O.
    International Journal of Clinical Oncology, 2005, 10 (5) : 333 - 337
  • [26] PHASE-I STUDY OF PACLITAXEL AND ESTRAMUSTINE - PRELIMINARY ACTIVITY IN HORMONE-REFRACTORY PROSTATE-CANCER
    HUDES, GR
    OBASAJU, C
    CHAPMAN, A
    GALLO, J
    MCALEER, C
    GREENBERG, R
    SEMINARS IN ONCOLOGY, 1995, 22 (03) : 6 - 11
  • [27] Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer
    Oudard, S
    Banu, E
    Beuzeboc, P
    Voog, E
    Dourthe, LM
    Hardy-Bessard, AC
    Linassier, C
    Scotté, F
    Banu, A
    Coscas, Y
    Guinet, F
    Poupon, MF
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3343 - 3351
  • [28] Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer
    Spitaleri, G.
    Matei, D. V.
    Curigliano, G.
    Detti, S.
    Verweij, F.
    Zambito, S.
    Scardino, E.
    Rocco, B.
    Nole, F.
    Ariu, L.
    De Pas, T.
    de Braud, F.
    De Cobelli, O.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 498 - 502
  • [29] Phase II study combining gefitinib with etoposide in patients with hormone-refractory metastatic prostate cancer (mHRPC) after docetaxel-based therapy
    Hauke, R. J.
    Loberiza, F. R.
    Elkahwaji, J. E.
    Townley, P. M.
    Bascom, G. K.
    Lin, M.
    Batra, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
    Eymard, J.-C.
    Priou, F.
    Zannetti, A.
    Ravaud, A.
    Lepille, D.
    Kerbrat, P.
    Gomez, P.
    Paule, B.
    Genet, D.
    Herait, P.
    Ecstein-Fraisse, E.
    Joly, F.
    ANNALS OF ONCOLOGY, 2007, 18 (06) : 1064 - 1070
12345